14 July 2022: Articles
Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series
Unusual setting of medical care
Guillermina Remaggi A* , Paola A. Ochoa A , Gonzalo M. Garate ADOI: 10.12659/AJCR.936505
Am J Case Rep 2022; 23:e936505
Table 1. Patient demographics and clinical characteristics at start of selinexor combined with bortezomib and dexamethasone (XVd) treatment.
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Age, years | 72 | 59 | 62 |
| Sex | Male | Female | Female |
| ECOG performance status | 2 | 1 | 3 |
| Cytogenetic abnormalities | NA | del(17p) | del(17p) |
| ISS disease staging | NA | 2 | 2 |
| Time since initial diagnosis, years | 13 | 7 | 5 |
| No. previous lines of therapy | 7 | 6 | 5 |
| Previous therapies | |||
| XVd treatment start-stop dates | 5 Feb 2020–16 Mar 2021 | 1 Oct 2019–10 Feb 2020 | 26 Nov 2019–1 Feb 2020 |
| ASCT – autologous stem-cell transplant; Cy – cyclophosphamide; CYBORD – cyclophosphamide, bortezomib, dexamethasone; Dara/Len/Dex – daratumumab, lenalidomide, dexamethasone; Dara/Pom/Dex – daratumumab, pomalidomide, dexamethasone; DCEP – dexamethasone, cyclophosphamide, etoposide, cisplatin; Dex – dexamethasone; ISS – International Staging System; KCd – carfilzomib, cyclophosphamide, dexamethasone; KRd – carfilzomib, lenalidomide, dexamethasone; KTD – carfilzomib, thalidomide, dexamethasone; NA – not available; Pom/Cy/Dex – pomalidomide, cyclophosphamide, dexamethasone; Rd – lenalidomide, dexamethasone; VRd – bortezomib, lenalidomide, dexamethasone; XVd – selinexor, bortezomib, dexamethasone. | |||